LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Docetaxel
Related studies linked through entity extraction aliases.
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
- Status
- COMPLETED
- Phase
- PHASE1
Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
- Status
- UNKNOWN
- Phase
- PHASE2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- Status
- SUSPENDED
- Phase
- PHASE2/PHASE3
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE2
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
- Status
- TERMINATED
- Phase
- PHASE3
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
- Status
- TERMINATED
- Phase
- PHASE2
XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Paclitaxel-bevacizumab in Advanced Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
GTX-RT in Borderline Resectable Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2